{"id":33875,"date":"2020-08-28T13:30:21","date_gmt":"2020-08-28T12:30:21","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33875"},"modified":"2023-05-05T22:43:45","modified_gmt":"2023-05-05T21:43:45","slug":"isabel-ottinger","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/drug-delivery-formulation-2019-speakers\/isabel-ottinger\/","title":{"rendered":"Isabel Ottinger"},"content":{"rendered":"
\n\n\t

Isabel Ottinger<\/h2>\n

Team Head Pharmaceutical Development Early Phase at Novartis Pharma AG<\/h4>\n\t

Isabel Ottinger is Team Head Pharmaceutical Development for Novel Biologic Entities (NBE) Early Phase since February 2018. With her team, she is responsible for the execution of all early phase NBE drug product development programs from first clinical dosage forms to post-POC formulations. In addition, she and her group take care about several NBE Drug Delivery programs in different therapeutic indications as LCM as well as first clinical formulation. Prior to her current role, Isabel was Team Head Pharmaceutical Development from 2014 to 2018.<\/p>\n

Her responsibilities included formulation development of all small molecule therapeutics for oral in early development standard and special dosage forms. Isabel has also led a global CMC team taking care of the technical development of several parenteral depot systems for peptides from early phase to MTA. Overall, she has more than 18 years of experience in pharmaceutical development for small and large molecules, early and late, parenteral and oral.<\/p>\n\t\t\t\t\t\t\t\"Isabel_Ottinger_BioTech_Pharma_Summit_Novartis_Profile_2\"\t\t\t\t\t\t\t\n

\n\tTitle: Sustained delivery of biologics: From benchtop to patients\n\t<\/h3>\n